USFDA Glare: USFDA scrutiny impacts drug approvals for domestic pharma companies | Delhi News
New Delhi: Regulatory scrutiny in the US has cast a dark cloud on approvals for new drugs from domestic generic biggies in the world’s most lucrative pharma market.ANDA (abbreviated new…